PE20121471A1 - Derivados de sulfonamida heterociclicos utiles como inhibidores de mek - Google Patents

Derivados de sulfonamida heterociclicos utiles como inhibidores de mek

Info

Publication number
PE20121471A1
PE20121471A1 PE2012000608A PE2012000608A PE20121471A1 PE 20121471 A1 PE20121471 A1 PE 20121471A1 PE 2012000608 A PE2012000608 A PE 2012000608A PE 2012000608 A PE2012000608 A PE 2012000608A PE 20121471 A1 PE20121471 A1 PE 20121471A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
helpful
heterocyclic sulfonamide
mek inhibitors
Prior art date
Application number
PE2012000608A
Other languages
English (en)
Inventor
Mark G Bock
Dinesh Chikkanna
Clive Mccarthy
Henrik Moebitz
Chetan Pandit
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43416908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20121471A1 publication Critical patent/PE20121471A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

SE REFIERE A UN COMPUESTO DERIVADO DE SULFONAMIDA HETEROCICLICO DE FORMULA (I) DONDE: R1a Y R1b SON HIDROXILO, CIANO, NITRO, ALQUILO C1-6, ALQUENILO C2-6, ENTRE OTROS; R2a ES H O ALQUILO C1-6; R2b ES ALQUILO C1-6, ALQUENILO C2-6, CICLOALQUILO, ARILO, ENTRE OTROS; R3 Y R4 SON H, ALQUILO C1-6, ALQUILO C1-6 OPCIONALMENTE SUSTITUIDO POR HALOGENO, HIDROXIALQUILO C1-6 O ALCOXILO C1-6, R5 ES H, HALOGENO, ALQUILO C1-3 O ALQUILO C1-3 SUSTITUIDO POR HALOGENO; X ES -N(R6)-; R6 ES H O ALQUILO C1-6; W ES NR22, O O S. R22 ES H, ALQUILO C1-6, ALQUENILO C2-6, CICLOALQUILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: [7-(4-BROMO-2-FLUORO-FENIL-AMINO)-6-METIL-5-OXO-1,2,3,5-TETRAHIDRO-IMIDAZO-[1,2-a]-PIRIDIN-8-IL]-AMIDA DEL ACIDO CICLOPROPAN-SULFONICO; [7-(2-FLUORO-4-YODO-FENIL-AMINO)-6-METIL-5-OXO-1,2,3,5-TETRAHIDRO-IMIDAZO-[1,2-a]-PIRIDIN-8-IL]-AMIDA DEL ACIDO 1-(2,3-DIHIDROXI-PROPIL)-CICLOPROPAN-SULFONICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES INHIBIDOR DE LA PROTEINA CINASA DE MEK SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS COMO CANCER E INFLAMACION
PE2012000608A 2009-11-04 2010-11-02 Derivados de sulfonamida heterociclicos utiles como inhibidores de mek PE20121471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2678CH2009 2009-11-04

Publications (1)

Publication Number Publication Date
PE20121471A1 true PE20121471A1 (es) 2012-11-01

Family

ID=43416908

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000608A PE20121471A1 (es) 2009-11-04 2010-11-02 Derivados de sulfonamida heterociclicos utiles como inhibidores de mek

Country Status (29)

Country Link
US (1) US8466289B2 (es)
EP (1) EP2496575B1 (es)
JP (1) JP5466767B2 (es)
KR (1) KR101398772B1 (es)
CN (1) CN102596951B (es)
AR (1) AR078900A1 (es)
AU (1) AU2010317167B2 (es)
BR (1) BR112012010519A2 (es)
CA (1) CA2779935A1 (es)
CL (1) CL2012001027A1 (es)
CO (1) CO6541547A2 (es)
CR (1) CR20120234A (es)
DO (1) DOP2012000127A (es)
EA (1) EA201200651A1 (es)
EC (1) ECSP12011878A (es)
ES (1) ES2487628T3 (es)
GT (1) GT201200138A (es)
IL (1) IL219113A0 (es)
MA (1) MA33721B1 (es)
MX (1) MX2012005293A (es)
MY (1) MY156209A (es)
NI (1) NI201200084A (es)
NZ (1) NZ599565A (es)
PE (1) PE20121471A1 (es)
TN (1) TN2012000153A1 (es)
TW (1) TW201139449A (es)
UY (1) UY33000A (es)
WO (1) WO2011054828A1 (es)
ZA (1) ZA201202530B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140034898A (ko) * 2011-06-09 2014-03-20 노파르티스 아게 헤테로시클릭 술폰아미드 유도체
EP3549584A1 (en) 2013-03-12 2019-10-09 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of inhibitors of mek, egfr and erbb2 in the treatment of kras-mutant lung cancer, and kras-mutant colon cancer
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
CN106518885B (zh) * 2016-10-26 2018-10-16 云南大学 1,3-二氮杂环并吡啶季铵盐类化合物及其中间体化合物、制备方法和应用
EP3752154A4 (en) * 2018-02-12 2021-12-29 Array Biopharma, Inc. Methods and combination therapy to treat biliary tract cancer
EP3773724A2 (en) 2018-04-12 2021-02-17 UMC Utrecht Holding B.V. Drug combinations for use in the treatment of ras-mutant cancer
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
RO119721B1 (ro) 1992-10-28 2005-02-28 Genentech Inc. Antagonişti ai factorului de creştere al celulelor vasculare endoteliale
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6140332A (en) 1995-07-06 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
PL190489B1 (pl) 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
ATE308527T1 (de) 1996-06-24 2005-11-15 Pfizer Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
ATE247724T1 (de) 1996-09-06 2003-09-15 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
DE59712968D1 (de) 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE69927790T2 (de) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
JP4731016B2 (ja) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
ES2265929T3 (es) 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60139506D1 (de) 2000-12-28 2009-09-17 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP2130820A1 (en) 2002-02-19 2009-12-09 Shionogi & Co., Ltd. Antipruritics
PT1912636E (pt) 2005-07-21 2014-07-24 Ardea Biosciences Inc Inibidores de n-(arilamino)-sulfonamida de mek
DK1934174T3 (da) * 2005-10-07 2011-08-01 Exelixis Inc Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
MX2008013097A (es) 2006-04-18 2008-10-27 Ardea Biosciences Inc Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona.
ES2547303T3 (es) * 2007-01-19 2015-10-05 Ardea Biosciences, Inc. Inhibidores de MEK
CA2686484A1 (en) 2007-05-11 2008-11-20 Bayer Schering Pharma Aktiengesellschaft Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity
JP5479337B2 (ja) 2007-07-30 2014-04-23 アルディア バイオサイエンス，インク． Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用
EP2227469B9 (en) * 2007-11-12 2014-09-10 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
PE20100747A1 (es) * 2008-04-21 2010-11-03 Novartis Ag Compuestos heterociclicos como inhibidores de mek
WO2009129938A1 (en) 2008-04-22 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted phenoxybenzamides
MX2010014559A (es) 2008-07-01 2011-03-04 Genentech Inc Heterociclos bicíclicos sustituidos y metodos de uso.
UY32486A (es) 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
JP2012524114A (ja) * 2009-04-21 2012-10-11 ノバルティス アーゲー Ｍｅｋ阻害剤としてのヘテロ環式化合物

Also Published As

Publication number Publication date
AU2010317167B2 (en) 2012-11-29
EP2496575B1 (en) 2014-04-30
JP5466767B2 (ja) 2014-04-09
ES2487628T3 (es) 2014-08-22
MX2012005293A (es) 2012-06-19
MY156209A (en) 2016-01-29
CA2779935A1 (en) 2011-05-12
AR078900A1 (es) 2011-12-14
CR20120234A (es) 2012-06-28
NZ599565A (en) 2013-05-31
WO2011054828A1 (en) 2011-05-12
TN2012000153A1 (en) 2013-12-12
KR101398772B1 (ko) 2014-05-27
US8466289B2 (en) 2013-06-18
CN102596951A (zh) 2012-07-18
US20110190334A1 (en) 2011-08-04
ECSP12011878A (es) 2012-07-31
BR112012010519A2 (pt) 2017-12-05
CO6541547A2 (es) 2012-10-16
AU2010317167A1 (en) 2012-05-03
ZA201202530B (en) 2013-01-30
IL219113A0 (en) 2012-06-28
TW201139449A (en) 2011-11-16
JP2013510118A (ja) 2013-03-21
MA33721B1 (fr) 2012-11-01
EA201200651A1 (ru) 2012-12-28
GT201200138A (es) 2014-03-27
CL2012001027A1 (es) 2012-08-03
EP2496575A1 (en) 2012-09-12
DOP2012000127A (es) 2012-08-31
NI201200084A (es) 2012-08-13
KR20120090078A (ko) 2012-08-16
UY33000A (es) 2011-06-30
CN102596951B (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
PE20121471A1 (es) Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
PE20080315A1 (es) DERIVADOS DE PIRAZOLO-[3,4-d]-PIRIMIDINAS COMO INHIBIDORES DE CINASA PI-3
PE20120120A1 (es) DERIVADOS DE 2H-PIRAZOLO[3,4-d]PIRIMIDINA-4,6(5H,7H)-DIONA, COMO INHIBIDORES DE PDE1
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
SE0402735D0 (sv) Novel compounds
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
PE20120107A1 (es) Inhibidores de proteina cinasa
NO20090580L (no) Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
MX2012002179A (es) Compuestos heterociclicos de oxima.
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
PE20121025A1 (es) Compuestos de benzoxazepina como inhibidores de la p13k
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20141557A1 (es) Derivado de pirazoloquinolina
EA201270339A1 (ru) Замещенные производные ксантина
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NZ602041A (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase

Legal Events

Date Code Title Description
FD Application declared void or lapsed